A study has demonstrated that erythropoietin prevents chronic allograft injury via mechanisms beyond anemia correction. In contrast to erythropoietin, blood transfusions did not prevent chronic allograft injury in rats despite normalization of hemoglobin levels. The researchers suggest that the effects of erythropoietin might be mediated by the upregulation of angiogenic and antiapoptotic factors.